

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION OF

Confirmation No. 4921

Antonio J. GRILLO-LOPEZ et al.

Group Art Unit: 1642

Application Serial No. 09/840,872

Examiner: Susan Ungar

Filed: April 25, 2001

Title: INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF  
CENTRAL NERVOUS SYSTEM LYMPHOMAS

\* \* \* \* \*

**AMENDMENT PURSUANT TO 37 C.F.R. 1.111**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the official action [non-final rejection] dated November 29, 2006, wherein the claims were rejected under 35 U.S.C. § 103(a), and under the judicially created doctrine of obviousness-type double patenting. A declaration pursuant to 37 C.F.R. § 1.132 is also submitted herewith. A petition for a two-month extension of time is hereby made, along with payment of the requisite fee under 37 C.F.R. § 1.17(a).